Protalix BioTherapeutics (PLX) Income from Continuing Operations (2010 - 2026)

Protalix BioTherapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 18388000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 608.1% year-over-year to 18388000.0; the TTM figure through Mar 2026 stood at 16885000.0 (up 105.41% YoY), while the FY2025 annual figure was 5235000.0, down 169.99% from the prior year.
• Income from Continuing Operations was 18388000.0 for Q1 2026 at Protalix BioTherapeutics, up from 4312000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 18388000.0 in Q1 2026 to a low of 24763000.0 in Q4 2023.
• Historically, Income from Continuing Operations has averaged 436705.88 across 5 years, with a median of 2286000.0 in 2022.
• The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations tumbled 671.43% in 2023, then soared 608.1% in 2026.
• A 5-year view of Income from Continuing Operations shows it stood at 3210000.0 in 2022, then sank by 671.43% to 24763000.0 in 2023, then jumped by 143.64% to 10806000.0 in 2024, then plunged by 139.9% to 4312000.0 in 2025, then soared by 526.44% to 18388000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 18388000.0 (Q1 2026), 4312000.0 (Q4 2025), and 2414000.0 (Q3 2025), per Business Quant data.